- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NT PHARMA (01011): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| Mi | NT PHARMA (01011): FORM OF PROXY FOR USE AT EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| Mi | NT PHARMA (01011): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDER | 1 | HKEx | ||
| Mi | NT PHARMA (01011): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDER | 2 | HKEx | ||
| CHINA NT PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | NT PHARMA (01011): MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING THE ISSUE OF CONSIDERATION ... | 1 | HKEx | ||
| 18.12. | NT PHARMA (01011): SUPPLEMENTAL ANNOUNCEMENT - MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100% OF THE ISSUED SHARES IN THE TARGET COMPANIES INVOLVING ... | 1 | HKEx | ||
| 25.11. | NT PHARMA (01011): CHANGES OF (1) COMPANY SECRETARY, (2) AUTHORISED REPRESENTATIVE AND (3) AGENT FOR THE ACCEPTANCE OF SERVICE OF PROCESS AND NOTICES ... | - | HKEx | ||
| 24.11. | NT PHARMA (01011): SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 AND INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE ... | 1 | HKEx | ||
| 17.10. | NT PHARMA (01011): RESIGNATION OF (1) COMPANY SECRETARY, (2) AUTHORISED REPRESENTATIVE AND (3) AGENT FOR THE ACCEPTANCE OF SERVICE OF PROCESS AND NOTICES ... | 1 | HKEx | ||
| 17.10. | NT PHARMA (01011): UPDATE IN RELATION TO THE DISCLAIMER OF OPINION ON GOING CONCERN SET OUT IN THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 | 1 | HKEx | ||
| 05.09. | NT PHARMA (01011): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDER | - | HKEx | ||
| 05.09. | NT PHARMA (01011): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDER | - | HKEx | ||
| 05.09. | NT PHARMA (01011): INTERIM REPORT 2025 | 1 | HKEx | ||
| 19.08. | NT PHARMA (01011): INSIDE INFORMATION AND RESUMPTION OF TRADING | 1 | HKEx | ||
| 19.08. | NT PHARMA (01011): TRADING HALT | - | HKEx | ||
| 18.08. | NT PHARMA (01011): CHANGE OF ADDRESS OF THE PRINCIPAL PLACE OF BUSINESS AND HEADQUARTERS | 1 | HKEx | ||
| 08.08. | NT PHARMA (01011): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| 30.07. | NT PHARMA (01011): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 2 | HKEx | ||
| 29.07. | NT PHARMA (01011): DATE OF BOARD MEETING | 1 | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,950 | -1,25 % | Nach der Trump-Unterschrift: Auch 2026 kein Ende der Leidenszeit? Canopy, Aurora, Tilray mit Kursbeben | © Foto: adobe.stock.comDie Spekulationen schossen ins Kraut, dass Trump eine Executive Order auf den Weg bringen würde, um den festgefahrenen Rescheduling-Prozess zu beschleunigen. Der Cannabis-Sektor... ► Artikel lesen | |
| CANOPY GROWTH | 1,192 | +5,49 % | Can Canopy Growth Stock Finally Recover in 2026, as Donald Trump Might Ease Cannabis Restrictions? | ||
| TILRAY BRANDS | 8,954 | +1,45 % | Tilray Brands, Inc. (TLRY)'s Potential Upside Meets a Cautious Consensus | ||
| DIGICANN VENTURES | 0,006 | -31,25 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SINOPHARM | 2,124 | -1,67 % | Sinopharm Group-Aktie heute gut behauptet: Aktienwert steigt (2,08 €) | Der Anteilsschein der Sinopharm Group notiert heute ein wenig fester. Zuletzt zahlten Investoren für das Wertpapier 2,08 Euro. Jahreschart der Sinopharm Group Ltd-Aktie, Stand 11.09.2025 Freuen können... ► Artikel lesen | |
| CSPC PHARMA | 0,946 | +7,20 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - DARATUMUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA | ||
| ORAMED PHARMACEUTICALS | 2,482 | +1,31 % | Oramed Pharmaceuticals Inc.: Oramed Reports Fiscal Third Quarter 2025 Financial Results | Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million
NEW YORK, Nov. 17, 2025 /PRNewswire/ --... ► Artikel lesen | |
| ADASTRA | 0,105 | 0,00 % | Adastra Holdings Ltd.: Adastra Holdings Announces Completion of Sale of Subsidiaries | Langley, British Columbia--(Newsfile Corp. - October 15, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) (the "Company") announces that it has completed the sale of all of the issued and outstanding... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,350 | +2,65 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| METRIOPHARM | - | - | MetrioPharm gains orphan drug status from EMA for MP1032 | ||
| BRIGHT MINDS BIOSCIENCES | 82,12 | -3,00 % | Cantor Fitzgerald bestätigt "Overweight" für Bright Minds Biosciences und sieht Potenzial in Hauptwirkstoff BMB-101 | ||
| BIOHAVEN | 11,145 | +3,96 % | Biohaven Ltd.: Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder | NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
| HARROW | 50,09 | -0,14 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,990 | +0,34 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| UNIVERSE PHARMACEUTICALS | 5,620 | +31,00 % | Universe Pharmaceuticals INC - 6-K, Report of foreign issuer |
Das Unternehmen CHINA NT PHARMA GROUP CO LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHINA NT PHARMA GROUP CO LTD finden Sie auf Wallstreet Online.